AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8065152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mg and 10 mg of mitomycin C IV on postoperative days 0 and 1, then tegafur at 600 mg/body daily PO from postoperative week 2 for 1 year.
Number of subjects: 336
Study 8065152 — intervention group
Group type: COMPARATOR
Intervention: Group B: 0.2 mg of mitomycin C per kg IV at 3, 6, 9, and 12 months after surgery.
Number of subjects: 336
Study 3338348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 62
Study 3338348 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular (IM) analgesia
Number of subjects: 62
Study 29461422 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and power training program (high-load barbell movements)
Number of subjects: 12
Study 29461422 — intervention group
Group type: COMPARATOR
Intervention: Bodyweight and rotational movement focused resistance training program (control)
Number of subjects: 12
Study 30359693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (anaerobic and aerobic exercises) for 12 weeks, 3 times per week, intensity increased from 40% to 70% HRR
Number of subjects: 20
Study 30359693 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 20
Study 26504102 — intervention group
Group type: COMPARATOR
Intervention: Risk Difference
Number of subjects: 531
Study 26504102 — intervention group
Group type: COMPARATOR
Intervention: Relative Risk
Number of subjects: 531
Study 26504102 — intervention group
Group type: COMPARATOR
Intervention: Ratio of Means
Number of subjects: 531
Study 26504102 — intervention group
Group type: COMPARATOR
Intervention: Standardized Mean Difference
Number of subjects: 531
Study 26504102 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous Presentations (Relative Risk and Risk Difference)
Number of subjects: 531
Study 24169022 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training related to depression (n=21)
Number of subjects: 40
Study 24169022 — intervention group
Group type: COMPARATOR
Intervention: No training (control group, n=19)
Number of subjects: 40
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg MF59(®) adjuvanted vaccine
Number of subjects: 661
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59(®) adjuvanted vaccine
Number of subjects: 661
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg non-adjuvanted vaccine
Number of subjects: 661
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg MF59(®) adjuvanted vaccine (adults)
Number of subjects: 661
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59(®) adjuvanted vaccine (elderly)
Number of subjects: 661
Study 22446638 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster administration after two priming doses
Number of subjects: 661
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MenACWY-CRM at 6 and 12 months
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of MenACWY-CRM at 12 months
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of MenC at 12 months
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MenACWY-CRM
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM given at 6 or 12 months
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (two doses)
Number of subjects: 175
Study 20033465 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC (one dose)
Number of subjects: 175
Study 20033465 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 175
Study 19214262 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakout sessions using actual legal cases
Number of subjects: 24
Study 15870217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1466
Study 15870217 — intervention group
Group type: COMPARATOR
Intervention: Non-drinkers
Number of subjects: 1466
Study 15221207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg capsules daily)
Number of subjects: 378
Study 15221207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule daily)
Number of subjects: 378
Study 10840355 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial portacaval shunt (10-mm diameter interposition portacaval H-graft)
Number of subjects: 46
Study 10840355 — intervention group
Group type: COMPARATOR
Intervention: Direct side-to-side portacaval shunt
Number of subjects: 46
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: MHI score
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: IADL score
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: RD Scale
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: History of falls during the 3 months before hospitalization
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: BADL score
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of incontinence
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: SA score
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CHP score
Number of subjects: 1889
Study 9100709 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in MHI, IADL, and BADL score
Number of subjects: 1889
Study 8173700 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg once daily
Number of subjects: 15
Study 8173700 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 15
Study 3456381 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped dental fear-reduction program
Number of subjects: 0
Study 3456381 — intervention group
Group type: COMPARATOR
Intervention: Videotaped placebo group
Number of subjects: 0
Study 2455089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological protection with coenzyme Q (5 mg/kg) and aprotinin (10,000 KIU/kg) administered intravenously every 12 hours post-surgery and a single dose intraoperatively.
Number of subjects: 50
Study 2455089 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with IABP.
Number of subjects: 50
Study 30285125 — intervention group
Group type: EXPERIMENTAL
Intervention: β2-agonist terbutaline (0.2 to 0.4 mg)
Number of subjects: 10
Study 30285125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29066444 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 200,000 IU followed by monthly 100,000 IU doses (n=71)
Number of subjects: 150
Study 29066444 — intervention group
Group type: COMPARATOR
Intervention: Placebo monthly (n=79)
Number of subjects: 150
Study 25946968 — intervention group
Group type: EXPERIMENTAL
Intervention: PAX Good Behavior Game (PAX GBG)
Number of subjects: 0
Study 24377531 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG) 7.5 g/day
Number of subjects: 60
Study 24377531 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamin (B12) 1500 μg/day
Number of subjects: 60
Study 24377531 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG)
Number of subjects: 60
Study 24377531 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamin (B12)
Number of subjects: 60
Study 21969500 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib maintenance therapy
Number of subjects: 889
Study 21969500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 19563428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute lower respiratory infection (ALRI) cases
Number of subjects: 1208
Study 19563428 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1208
Study 16460239 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus subgingival minocycline
Number of subjects: 26
Study 16460239 — intervention group
Group type: COMPARATOR
Intervention: SRP plus vehicle
Number of subjects: 26
Study 12382548 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 13
Study 10037386 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy transurethral microwave therapy
Number of subjects: 52
Study 10037386 — intervention group
Group type: COMPARATOR
Intervention: Terazosin
Number of subjects: 52
Study 8625038 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐lomustine/5‐FU/Leucovorin (MFL) regimen (methyl‐lomustine 110 mg/m2 on Day 1 of each 8-week cycle, 5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Number of subjects: 319
Study 8625038 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU and Leucovorin (FL) regimen (5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Number of subjects: 319
Study 8625038 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl‐lomustine/5‐FU/Leucovorin (MFL)
Number of subjects: 319
Study 8625038 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU and Leucovorin (FL)
Number of subjects: 319
Study 2158151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (2,500 U once per day)
Number of subjects: 250
Study 2158151 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 IU b.i.d.)
Number of subjects: 250
Study 7441728 — intervention group
Group type: EXPERIMENTAL
Intervention: High technical competence
Number of subjects: 192
Study 7441728 — intervention group
Group type: EXPERIMENTAL
Intervention: High social competence
Number of subjects: 192
Study 7441728 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 192
Study 7441728 — intervention group
Group type: COMPARATOR
Intervention: Low technical competence
Number of subjects: 192
Study 7441728 — intervention group
Group type: COMPARATOR
Intervention: Low social competence
Number of subjects: 192
Study 7441728 — intervention group
Group type: COMPARATOR
Intervention: Female physicians
Number of subjects: 192
Study 7441728 — intervention group
Group type: COMPARATOR
Intervention: Physicians with low physical attractiveness
Number of subjects: 192
Study 29249041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10 ketamine-propofol mixture (ketofol)
Number of subjects: 75
Study 29249041 — intervention group
Group type: COMPARATOR
Intervention: 1:5 ketamine-propofol mixture (ketofol)
Number of subjects: 75
Study 29249041 — intervention group
Group type: COMPARATOR
Intervention: 1:6.7 ketamine-propofol mixture (ketofol)
Number of subjects: 75
Study 28438209 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-episiotomy protocol (experimental group)
Number of subjects: 241
Study 28438209 — intervention group
Group type: COMPARATOR
Intervention: Selective episiotomy (control group)
Number of subjects: 241
Study 25575197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin Desensitizer with Optibond XTR
Number of subjects: 120
Study 25575197 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma with iBond
Number of subjects: 120
Study 25575197 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroPrime B with Xeno IV
Number of subjects: 120
Study 25575197 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond with no desensitizer
Number of subjects: 120
Study 25575197 — intervention group
Group type: COMPARATOR
Intervention: Control group without desensitizer
Number of subjects: 120
Study 24125620 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine (3 g within 250 ml normal saline for intravenous infusion)
Number of subjects: 120
Study 24125620 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 120
Study 24125620 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti‐heart failure drugs
Number of subjects: 120
Study 21360029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 41781
Study 21360029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions targeted toward men who have already undergone prostate cancer screening
Number of subjects: 41781
Study 21360029 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening encounter
Number of subjects: 41781
Study 18372471 — intervention group
Group type: EXPERIMENTAL
Intervention: CE MR angiography with 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 293
Study 16520206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular cups with cement spacers made from polyethylene integrated into the cup
Number of subjects: 407
Study 16520206 — intervention group
Group type: COMPARATOR
Intervention: Acetabular cups without cement spacers
Number of subjects: 407
Study 16520206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular cups with polyethylene spacers
Number of subjects: 407
Study 16520206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cups placed at an angle of 45.0 degrees to 50.5 degrees
Number of subjects: 407
Study 12897996 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid sedation during session 1
Number of subjects: 20
Study 12897996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (muscle relaxant) during session 2
Number of subjects: 20
Study 11131931 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency response alternatives/horizontal orientation (Condition A)
Number of subjects: 518
Study 11131931 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium frequency response alternatives/horizontal orientation (Condition B)
Number of subjects: 518
Study 11131931 — intervention group
Group type: COMPARATOR
Intervention: High frequency response alternatives/vertical orientation (Condition C)
Number of subjects: 518
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women (age > 65)
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly men (age > 65)
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women (Grade II deformity)
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly men (Grade II deformity)
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 40 and over
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 40 and over (Grade II lesions)
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly women vs elderly men
Number of subjects: 0
Study 8781047 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific female-to-male ratio
Number of subjects: 0
Study 1814768 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite restorations (n = 64)
Number of subjects: 43
Study 1814768 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations (n = 55)
Number of subjects: 43
Study 6849473 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (exit interview)
Number of subjects: 400
Study 6849473 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (home visit)
Number of subjects: 400
Study 6849473 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (small group sessions)
Number of subjects: 400
Study 6849473 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 400
Study 6849473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 31595773 — intervention group
Group type: EXPERIMENTAL
Intervention: BBFC + PGA
Number of subjects: 188
Study 30478855 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI)
Number of subjects: 0
Study 30478855 — intervention group
Group type: COMPARATOR
Intervention: Standard breastfeeding education
Number of subjects: 0
Study 29365058 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly 18FDG-PET/CT
Number of subjects: 239
Study 29365058 — intervention group
Group type: COMPARATOR
Intervention: Usual monitoring alone
Number of subjects: 239
Study 27436602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel CPS
Number of subjects: 65
Study 27436602 — intervention group
Group type: COMPARATOR
Intervention: Control (no Sentinel CPS)
Number of subjects: 65
Study 24449597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 50
Study 24449597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 50
Study 24449597 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 50
Study 24041270 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (405 mg/4 weeks, 300 mg/2 weeks, 150 mg/2 weeks)
Number of subjects: 1064
Study 24041270 — intervention group
Group type: COMPARATOR
Intervention: Sub-therapeutic olanzapine long-acting injection (45 mg/4 weeks)
Number of subjects: 1064
Study 24041270 — intervention group
Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 1064
Study 20797571 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease and Sagliker syndrome (SS)
Number of subjects: 13
Study 17938978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 2721
Study 17938978 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin prophylaxis
Number of subjects: 2721
Study 16021173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 617
Study 16021173 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 617
Study 12509555 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carotid artery intimal-medial thickness (cIMT)
Number of subjects: 32
Study 12509555 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cIMT
Number of subjects: 32
Study 12509555 — intervention group
Group type: EXPERIMENTAL
Intervention: cIMT
Number of subjects: 32
Study 12509555 — intervention group
Group type: EXPERIMENTAL
Intervention: cIMT and LVMI
Number of subjects: 32
Study 11005942 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 11005942 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8883119 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day)
Number of subjects: 112
Study 8883119 — intervention group
Group type: COMPARATOR
Intervention: calcium (500 mg/day)
Number of subjects: 112
Study 1520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test (subject-specific MCQ) before teaching demonstration on vascular disorders
Number of subjects: 0
Study 1520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test (subject-specific MCQ) before teaching demonstration on traumatology
Number of subjects: 0
Study 1520160 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-test marks compared to pre-test marks
Number of subjects: 0
Study 3917316 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone given by mouth in increasing doses
Number of subjects: 10
Study 3917316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31369392 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intermittent training (HIIT), 3 days/week for 6 weeks
Number of subjects: 20
Study 30001215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency neurotomy of medial branches
Number of subjects: 71
Study 27029823 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax 50 mg (uncoated tablet)
Number of subjects: 39
Study 27029823 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax film-coated 100 mg tablet after low-fat breakfast
Number of subjects: 39
Study 27029823 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax film-coated 100 mg tablet after high-fat breakfast
Number of subjects: 39
Study 27029823 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax under fasting conditions
Number of subjects: 39
Study 24859237 — intervention group
Group type: EXPERIMENTAL
Intervention: Truth distractors
Number of subjects: 0
Study 24859237 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased proportion of truth distractor trials
Number of subjects: 0
Study 24859237 — intervention group
Group type: COMPARATOR
Intervention: Lie distractors
Number of subjects: 0
Study 22260966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol alone
Number of subjects: 0
Study 22260966 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and nicotine combined
Number of subjects: 0
Study 22260966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety after speech stressor with alcohol and nicotine
Number of subjects: 0
Study 19797411 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-only wear of upper and lower Hawley retainers for 1 year
Number of subjects: 67
Study 19797411 — intervention group
Group type: COMPARATOR
Intervention: 6 months full-time followed by 6 months night-only wear of upper and lower Hawley retainers
Number of subjects: 67
Study 18312743 — intervention group
Group type: COMPARATOR
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 30
Study 18312743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 30
Study 18312743 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal Dialysis (PD)
Number of subjects: 30
Study 18312743 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD and HD patients
Number of subjects: 30
Study 15562388 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 22
Study 15562388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 22
Study 15562388 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 12218282 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation D
Number of subjects: 10
Study 12218282 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 10